Roaa Alsolaimani

Dr. Roaa Alsolaimani

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2016 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
AKAbdullah Kashgary
Abdullah Kashgary
JSJessica Sontrop
Jessica Sontrop
LLLihua Li
Lihua Li
AAAhmed A. Al-Jaishi
Ahmed A. Al-Jaishi
ZHZainab N. Habibullah
Zainab N. Habibullah
WCWilliam Clark
William Clark
Evidence on the role of plasma exchange for treating recurrent post-transplant focal segmental glomerulosclerosis (FSGS) comes largely from individual cases and uncontrolled series. We conducted a systematic review and meta-analysis to estimate the remission rate after treatment with plasma exchange, and to determine if remission varied with patient or treatment characteristics. We searched MEDLINE, EMBASE, Science Citation Index Expanded, and the Conference Proceedings Citation Index (Science and BIOSIS) for studies of patients with post-transplant recurrent FSGS who were treated with plasma exchange after recurrence (1950–2012). Of 678 studies screened, 77 met our inclusion criteria: 34 case reports (45 patients) and 43 case series (378 patients). We extracted patient-level data from each study and used random-effects models to calculate remission, defined as proteinuria <3.5 g/day (partial) or 7 g/day at recurrence was inversely associated with remission (OR = 0.43; 95 % CI: 0.19 to 0.97). Age and type of kidney transplant (living vs. deceased) did not associate with remission. In this systematic review of patients with recurrent post-transplant FSGS, 71 % of patients achieved full or partial remission after treatment with plasma exchange; however, extensive missing data and lack of a control group limit any conclusions on causality.

14 November 2022 in Cureus
Verified
Journal Article
Open access
RARoaa Alsolaimani
Roaa Alsolaimani
We describe a case of systemic lupus erythematosus (SLE) presenting initially with mesenteric vasculitis and urinary system involvement without any other SLE clinical features and a weakly positive antinuclear antibody on initial testing. She is a 15-year-old healthy female who presented with severe abdominal pain, diarrhea, vomiting, and weight loss for more than one month. She later developed cystitis and bilateral hydronephrosis. Her repeated autoantibody panel and computed tomography of the abdomen were diagnostic for mesenteric vasculitis related to SLE, and a colonic biopsy showed occlusive thromboangiopathy related to associated antiphospholipid antibody syndrome. She responded well to intravenous methylprednisolone, rituximab, and anticoagulation. Mycophenolate mofetil and hydroxychloroquine were used later for maintenance treatment. Lupus mesenteric vasculitis (LMV) is rare but a serious, potentially life-threatening, gastrointestinal complication associated with SLE. Clinical features are not very specific, making them challenging to diagnose. Thus, early diagnosis requires a high index of suspension especially in cases presenting with gastrointestinal symptoms without a previously established diagnosis of SLE. LMV occurs as an initial presentation of SLE in children more than adults. So, it is wise to investigate children presenting with gastrointestinal manifestations and involvement of other organs especially the urinary system thoroughly with autoantibodies and abdominal imaging to rule out or confirm the diagnosis of LMV and to start treatment early and aggressively.

3 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MMMohammad A Mustafa
Mohammad A Mustafa
YBYasser Bawazir
Yasser Bawazir
MMMariam S Mukhtar
Mariam S Mukhtar
MMMahmoud Mosli
Mahmoud Mosli
Nadeem Shafique ButtNadeem Shafique Butt
Nadeem Shafique Butt
RARoaa Alsolaimani
Roaa Alsolaimani
Background: Inflammatory bowel disease (IBD) is associated with chronic pain and reduced quality of life, even in the absence of active intestinal inflammation. International studies suggest that fibromyalgia (FM), a chronic pain disorder characterized by widespread musculoskeletal pain, fatigue, sleep disturbance, and multiple somatic symptoms, is more prevalent among patients with IBD than among the general population. However, data from Saudi Arabia are limited. Methods: This cross-sectional study was conducted at King Abdulaziz University Hospital in Jeddah, Saudi Arabia, during July and August of 2024. Patients with biopsy-confirmed IBD were identified from hospital records and contacted by phone to screen for FM using a validated Arabic version of the Fibromyalgia Rapid Screening Tool. Demographic data, comorbidities, medication exposure, IBD characteristics, disease activity, and laboratory parameters were extracted from the medical records and compared between patients with and without FM. Results: Of 274 patients with IBD (mean age 30.9 ± 9.2 years; 56.9% male), 51 (18.6%; 95% CI 14.2–23.7) met criteria for FM. Patients with FM tended to be older than those without and were more likely to have comorbidities, particularly thyroid disorders, as well as low Vitamin D levels. Prior 5-aminosalicylic acid use was also more common among patients with FM. Inflammatory markers, hematological indices, IBD phenotypes, and disease activity were similar between the groups. Conclusions: Saudi patients with IBD often have comorbid FM. Routine FM screening in IBD clinics may help avoid misattributing central pain to active inflammation and unnecessary treatment escalation.

3 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MMMariam S. Mukhtar
Mariam S. Mukhtar
MMMahmoud Mosli
Mahmoud Mosli
Nadeem Shafique ButtNadeem Shafique Butt
Nadeem Shafique Butt
SBSaud Bamousa
Saud Bamousa
SASharefah Abdullah Alqarni
Sharefah Abdullah Alqarni
RARoaa Alsolaimani
Roaa Alsolaimani
Background: Fatigue is a common and distressing symptom in inflammatory bowel disease (IBD), yet it is rarely addressed in routine care. Most available evidence comes from Western and East Asian populations, with limited data from the Middle East. Objectives: To estimate the prevalence of fatigue in Saudi patients with IBD, using the Arabic‑validated Brief Fatigue Inventory (BFI‑A), and to examine associations with demographic, clinical, treatment, and laboratory factors. Methods: This cross-sectional study was conducted at King Abdulaziz University Hospital, Saudi Arabia, between March and December 2025. Patients aged ≥12 years with histologically-confirmed IBD completed a structured telephone interview. Demographic characteristics, comorbidities, IBD control scores, Montreal classification, medication history, and laboratory results were collected. Patients experiencing severe flares, hospitalization, or another primary condition likely to explain fatigue were excluded. Fatigue severity was classified as none, mild, moderate, or severe. Associations were tested using chi-square and Kruskal–Wallis tests. Results: Among 286 patients (mean age, 30.8 ± 9.1 years; 57.7% male), 23.1% reported mild fatigue, 36.4% moderate fatigue, and 19.2% severe fatigue on the BFI‑A. Fatigue severity was not associated with demographic factors, IBD type or phenotype, treatment exposure, or most laboratory parameters. Only serum iron (p = 0.011) and erythrocyte sedimentation rate (p = 0.023) differed across fatigue categories, without a clear dose–response pattern. Conclusions: Fatigue affects more than half of Saudi patients with IBD and is not explained by routine clinical or laboratory factors. Routine fatigue assessment and attention to biopsychosocial contributors may improve IBD care.

13 April 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MMMariam S. Mukhtar
Mariam S. Mukhtar
MMMahmoud Mosli
Mahmoud Mosli
Nadeem Shafique ButtNadeem Shafique Butt
Nadeem Shafique Butt
SBSaud Bamousa
Saud Bamousa
SASharefah Abdullah Alqarni
Sharefah Abdullah Alqarni
RARoaa Alsolaimani
Roaa Alsolaimani
Background: Fatigue is a common and distressing symptom in inflammatory bowel disease (IBD), yet it is rarely addressed in routine care. Most available evidence comes from Western and East Asian populations, with limited data from the Middle East. Objectives: To estimate the prevalence of fatigue in Saudi patients with IBD, using the Arabic-validated Brief Fatigue Inventory (BFI-A), and to examine associations with demographic, clinical, treatment, and laboratory factors. Methods: This cross-sectional study was conducted at King Abdulaziz University Hospital, Saudi Arabia, between March and December 2025. Patients aged ≥12 years with histologically confirmed IBD completed a structured telephone interview. Demographic characteristics, comorbidities, IBD control scores, Montreal classification, medication history, and laboratory results were collected. Patients experiencing severe flares, hospitalization, or another primary condition likely to explain fatigue were excluded. Fatigue severity was classified as none, mild, moderate, or severe. Associations were tested using chi-square and Kruskal–Wallis tests. Results: Among 286 patients (mean age, 30.8 ± 9.1 years; 57.7% male), 23.1% reported mild fatigue, 36.4% moderate fatigue, and 19.2% severe fatigue on the BFI-A. Fatigue severity was not associated with demographic factors, IBD type or phenotype, treatment exposure, or most laboratory parameters. Only serum iron (p = 0.011) and erythrocyte sedimentation rate (p = 0.023) differed across fatigue categories, without a clear dose–response pattern. Conclusions: Fatigue affects more than half of Saudi patients with IBD and is not explained by routine clinical or laboratory factors. Routine fatigue assessment and attention to biopsychosocial contributors may improve IBD care.